These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 37360536)

  • 1. Pharmacovigilance in the Caribbean Countries: an Overview.
    Walker KEW; Bankay R; Jankie S; Dhingra S
    Curr Pharmacol Rep; 2023 May; ():1-11. PubMed ID: 37360536
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacovigilance in India, Uganda and South Africa with reference to WHO's minimum requirements.
    Maigetter K; Pollock AM; Kadam A; Ward K; Weiss MG
    Int J Health Policy Manag; 2015 Mar; 4(5):295-305. PubMed ID: 25905480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacovigilance in resource-limited countries.
    Olsson S; Pal SN; Dodoo A
    Expert Rev Clin Pharmacol; 2015; 8(4):449-60. PubMed ID: 26041035
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fighting trafficking of falsified and substandard medicinal products in Russia.
    Fayzrakhmanov NF
    Int J Risk Saf Med; 2015; 27 Suppl 1():S37-40. PubMed ID: 26639702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacovigilance of herbal medicines: Concerns and future prospects.
    Choudhury A; Singh PA; Bajwa N; Dash S; Bisht P
    J Ethnopharmacol; 2023 Jun; 309():116383. PubMed ID: 36918049
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of a checklist for the assessment of pharmacovigilance guidelines in Southern Africa: a document review.
    Makhene NL; Steyn H; Vorster M; Lubbe MS; Burger JR
    Ther Adv Drug Saf; 2023; 14():20420986221143272. PubMed ID: 36713000
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Public health interventions to protect against falsified medicines: a systematic review of international, national and local policies.
    Hamilton WL; Doyle C; Halliwell-Ewen M; Lambert G
    Health Policy Plan; 2016 Dec; 31(10):1448-1466. PubMed ID: 27311827
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pacific Island Pharmacovigilance: The Need for a Different Approach.
    McEwen J; Vestergaard LS; Sanburg AL
    Drug Saf; 2016 Oct; 39(10):891-4. PubMed ID: 27364632
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Funding and financial sustainability of pharmacovigilance: suggested models for funding pharmacovigilance in resource-limited African countries.
    Isah AO; Opadeyi AO; Tumwijukye H; Cobelens F; Smith D; Ndomondo-Sigonda M; Harmark L; Tanui P; Tiemersma E; Mmbaga BT; Mahlangu G; Ayinbuomwan SA; Soulaymani R; Pandit JM
    Ther Adv Drug Saf; 2023; 14():20420986231188836. PubMed ID: 37529763
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Knowledge, attitudes and practice regarding pharmacovigilance and adverse drug reaction reporting among physicians and pharmacists in Egypt: a step toward personalized medicine implementation.
    Aziz AA; Rogers S; Hassanien O; Shalaby L; Nagy M
    Per Med; 2022 Nov; 19(6):495-507. PubMed ID: 36239598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Knowledge, attitude, practice and barriers towards pharmacovigilance and adverse drug reactions reporting among healthcare professionals in Turkey: a systematic review.
    Khan Z; Karatas Y; Martins MAP; Jamshed S; Rahman H
    Curr Med Res Opin; 2022 Jan; 38(1):145-154. PubMed ID: 34694167
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacovigilance activities in ASEAN countries.
    Suwankesawong W; Dhippayom T; Tan-Koi WC; Kongkaew C
    Pharmacoepidemiol Drug Saf; 2016 Sep; 25(9):1061-9. PubMed ID: 27174034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Challenges and lessons learned from four years of planning and implementing pharmacovigilance enhancement in sub-Saharan Africa.
    Stegmann JU; Jusot V; Menang O; Gardiner G; Vesce S; Volpe S; Ndalama A; Adou F; Ofori-Anyinam O; Oladehin O; Mendoza YG
    BMC Public Health; 2022 Aug; 22(1):1568. PubMed ID: 35978276
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of Pharmacovigilance System in India and Paradigm of Pharmacovigilance Research: An Overview.
    Singh P; Vaishnav Y; Verma S
    Curr Drug Saf; 2023; 18(4):448-464. PubMed ID: 36200243
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adverse event reporting tools and regulatory measures in India through outcome of Pharmacovigilance Programme of India.
    Prakash J; Sachdeva R; Shrivastava TP; Jayachandran CV; Sahu A
    Indian J Pharmacol; 2021; 53(2):143-152. PubMed ID: 34100398
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacovigilance in China: development and challenges.
    Zhao Y; Wang T; Li G; Sun S
    Int J Clin Pharm; 2018 Aug; 40(4):823-831. PubMed ID: 30051225
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of the Current State of Pharmacovigilance System in Pakistan Using Indicator-Based Assessment Tool.
    Khan MAA; Hamid S; Ur-Rehman T; Babar ZU
    Front Pharmacol; 2021; 12():789103. PubMed ID: 35095498
    [No Abstract]   [Full Text] [Related]  

  • 19. Pharmacovigilance in Israel - tools, processes, and actions.
    Schwartzberg E; Berkovitch M; Dil Nahlieli D; Nathan J; Gorelik E
    Isr J Health Policy Res; 2017 Aug; 6(1):29. PubMed ID: 28760141
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacovigilance activities in 55 low- and middle-income countries: a questionnaire-based analysis.
    Olsson S; Pal SN; Stergachis A; Couper M
    Drug Saf; 2010 Aug; 33(8):689-703. PubMed ID: 20635827
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.